Neurofibromatosis Type 1

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Neurofibromatosis Type 1 Tumor Early Detection Study

Natural History Study of Patients With Neurofibromatosis Type I

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

Pediatric Long-Term Follow-up and Rollover Study

Interventions for Reading Disabilities in NF1

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

Familial Investigations of Childhood Cancer Predisposition

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Gait in Young Children With NF1

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

PASS of Paediatric Patients Initiating Selumetinib

FARD (RaDiCo Cohort) (RaDiCo-FARD)